Losartan and diabetic nephropathy: Commentaries on the RENAAL study

Cardiovascular Diabetology

Volumn 1, Issue , 2002, Pages

  Fisman, Enrique Z ^a,b   Tenenbaum, Alexander ^a,b   Motro, Michael ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Angiotensin receptor blockers; Clinical trials; Diabetes mellitus; Losartan; Nephropathy; RENAAL study

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ATENOLOL; CREATININE; GLIBENCLAMIDE; LOSARTAN; PLACEBO; SULFONYLUREA;

ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; GLUCOSE METABOLISM; HEART INFARCTION; HEART PERFORMANCE; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; METHODOLOGY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZATION; TREATMENT OUTCOME;

EID: 0348118425     PISSN: 14752840     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2840-1-2     Document Type: Article

References (16)

1. Brenner BM, Cooper ME, de Zeeuw D, Keane WK, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, et al: Effects of losartan on renal ands cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869
2. Skali H, Solomon SD, Pfeffer MA: Are we asking too much of our trials? Am Heart 2002, 143:1-3
3. Fisman EZ, Motro M, Tenenbaum A, Boyko V, Mandelzweig L, Behar S: Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis. Am Heart J 2001, 41:485-490
4. McCulloch DK, Glasgow RE, Hampson SE, Wagner E: A systemic approach to diabetes management in the post-DCCT era. Diabetes Care 1994, 17:765-769
5. Tenenbaum A, Fisman EZ, Boyko V, Goldbourt U, Graff E, Shemesh J, Shotan A, Reicher-Reiss H, Behar S, Motro M: Hypertension in diet versus pharmacologically treated diabetics: mortality over a 5-year follow-up. Hypertension 1999, 33:1002-1007
6. Brady PA, Terzic A: The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998, 31:950-956
7. Fisman EZ, Tenenbaum A, Boyko V, Benderly M, Adler Y, Friedensohn A, Kohanovski M, Rotzak R, Schneider H, Behar S, Motro M: Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001, 24:151-158
8. Olsson J, Lindberg G, Gottsater M, Lindwall K, Sjostrand A, Tisell A, Melander A: Increased mortality in Type 1 diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000, 43:558-560
9. Yusuf S, Negassa A: Choice of clinical outcomes in randomized trials of heart failure therapies: Disease-specific or overall outcomes? Am Heart J 2002, 143:22-28
10. O'Connor CM, Gattis WA, Ryan TJ: The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials. Am Heart J 2000, 139:S143-154
11. Federal Drug Administration: New drug, antibiotic and biological drug product regulations: accelerated approval. Proposed rule. 57 Federal Register 13234-13242, Washington 1992
12. Temple R: Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999, 282:790-795
13. Denker BM, Brenner BM: Cardinal manifestations of renal disease. In: Harrison's Principles of Internal Medicine 1998, 258
14. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860
15. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259
16. Lindholm LH, Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1010